272
Participants
Start Date
December 12, 2016
Primary Completion Date
February 28, 2023
Study Completion Date
February 28, 2023
Ravulizumab
All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilogram (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
Eculizumab
All treatments were given as IV infusions. Participants were administered induction doses of 600 mg followed by maintenance doses of 900 mg.
Research Site, Taipei
Research Site, Taichung
Research Site, Brussels
Research Site, Leuven
Research Site, Hasselt
Research Site, Linz
Research Site, Perth
Research Site, Bangkok
Research Site, Goyang-si
Research Site, Bangkok
Research Site, George
Research Site, Belgrade
Research Site, Tallinn
Research Site, Kota Bharu
Research Site, Kota Bharu
Research Site, Suwon
Research Site, Milan
Research Site, Incheon
Research Site, Eskişehir
Research Site, Madrid
Research Site, Majadahonda
Research Site, Montpellier
Research Site, Daejeon
Research Site, Rennes
Research Site, Vicenza
Research Site, Junggu
Research Site, Ulsan
Research Site, Essen
Research Site, Changhua
Research Site, Florence
Research Site, Aachen
Research Site, JinJoo
Research Site, Ascoli Piceno
Research Site, Monterrey
Research Site, Pierre-Bénite
Research Site, Tainan City
Research Site, Uppsala
Research Site, Paris
Research Site, Fort Worth
Research Site, Johor Bahru
Research Site, Napoli
Research Site, Poitiers
Research Site, Limoges
Research Site, Kota Kinabalu
Research Site, Ulm
Research Site, Los Angeles
Research Site, Songkhla
Research Site, Whittier
Research Site, Kuching
Research Site, Sibu
Research Site, Hualien City
Research Site, Miri
Research Site, Moscow
Research Site, Singapore
Research Site, Moscow
Research Site, Seoul
Research Site, Arkhangelsk
Research Site, Murmansk
Research Site, Petrozavodsk
Research Site, Saint Petersburg
Research Site, Rostov-on-Don
Research Site, Saratov
Research Site, Ufa
Research Site, Kirov
Research Site, Novosibirsk
Research Site, Omsk
Research Site, Barnaul
Research Site, Irkutsk
Research Site, Buenos Aires
Research Site, Buenos Aires
Research Site, Córdoba
Research Site, Vienna
Research Site, Rio de Janeiro
Research Site, São Paulo
Research Site, Prague
Research Site, Tokorozawa-shi
Research Site, Tokyo
Research Site, Saint Petersburg
Research Site, Leeds
Research Site, Salvador
Research Site, São Paulo
Research Site, Edmonton
Research Site, Toronto
Research Site, Pilsen
Research Site, Bunkyō City
Research Site, Bunkyō City
Research Site, Fukuoka
Research Site, Fukushima
Research Site, Hamamatsu
Research Site, Kanazawa
Research Site, Kitakyusyu-shi
Research Site, Koshigaya-shi
Research Site, Kumamoto
Research Site, Nagoya
Research Site, Nishinomiya-shi
Research Site, Ogaki-shi
Research Site, Okayama
Research Site, Okayama
Research Site, Osakasayama-shi
Research Site, Sapporo
Research Site, Shimotsuke-shi
Research Site, Shinjuku-ku
Research Site, Shinjuku-ku
Research Site, Suita
Research Site, Toyoake-shi
Research Site, Tsukuba
Research Site, Wakayama
Research Site, Gdansk
Research Site, Warsaw
Research Site, Jeonju
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Songpa-gu
Research Site, Airdrie
Research Site, London
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY